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The applicability of UCB transplantation had been historically limited by the small cell number available from a single unit. 4 Over the past decade, the utilization of double UCB (dUCB) unit grafts was shown to, at least in part, overcome the cell dose limitation and has been adopted by several institutions. 5, 6 Our group 7 and others 5, 8 have shown that despite the infusion of two UCB units, in the vast majority of cases only a single unit will predominate and provide long-term lympho-hematopoietic Figure 1 . Panels (a) to (d) describe the gating strategy for CXCR4 expression. Flow cytometry was performed on the FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) using CellQuest Pro Software (BD Biosciences). Samples for flow cytometric analysis were obtained from the final product before its release to the transplant floor and were stained and analyzed within 24 h of thaw without fixation. Briefly, aliquots containing 5 Â 10 5 CB cells were incubated with fluorochrome-conjugated monocolonal antibodies at 4 0 C for 20 min. To lyse the red blood cells, the samples were treated with Optilyse B (Beckman Coulter, Brea, CA, USA) as per manufacturer's instructions. Samples were stained for CD45 (PerCP, BD Biosciences), CD34 (APC, BD Biosciences, ), CXCR4 (PE, BD Biosciences), CD33 (FITC, BD Biosciences) and the corresponding fluorochrome-conjugated isotype controls (BD Biosciences). CXCR4 was substituted by CD38 (PE, BD Biosciences) in other tube set. Results were analyzed using FlowJo Software (TreeStar, Ashland, OR, USA). CD34 subpopulation was determined by creating a gate on the lymphocyte population followed by a plot of CD34 (y-axis)/forward scatter to select the single CD34-positive population. Similarly, following the lymphocyte population, a plot of CD34 (y-axis)/CD33 (x-axis) cells was determined to select the double-positive population. Another plot of CD34 (y-axis)/CD38 (x-axis) cells was determined to select the CD34 þ /CD38 À subpopulation (a). Next, a plot of CD34 (y-axis)/CD45 (x-axis) cells was determined to select the double-positive population that represents progenitor/stem cell subpopulation (b). Letters to the Editor recovery. Available data shows that UCB unit predominance is influenced by the T-cell content an interaction between T cells from both donor units. 5, 7 Identifying additional factors that determine the long-term predominant unit after dUCB transplantation will allow us to further refine UCB graft selection, and potentially improve outcomes. Thus, we studied whether the expression of CXCR4 on UCB CD34 þ cells and different CD34 þ cells subsets were also involved in unit predominance after dUCB transplantation.
We studied patients with hematological malignancies undergoing dUCB transplantation after myeloablative (MA) or nonmyeloablative (NMA) conditioning regimens at the University of Minnesota between 2005 and 2009. To be included in this analysis, patients were required to have achieved neutrophil engraftment with chimerism and had post-thaw flow cytometry data for the two UCB donor units. Patient demographics, laboratory and engraftment data were prospectively collected and available from the University of Minnesota Blood and Marrow Transplant Database. Graft selection, conditioning, immunosuppressive regimens and supportive care have been previously reported. 4, 9 A total of 68 patients were included in this analysis. In all, 41 patients (60%) were male. The majority of the patients (62%, n ¼ 42) were older than 35 years old. The median recipient weight was 82 kg (range: 22-145 kg). Most patients received a unit with at least 1 HLA mismatch (54%, n ¼ 37), and in 37% of the cases (n ¼ 25), both units were 4/6 HLA matched with the recipient. Acute leukemias were the indication for transplantation in 52% of the cases (n ¼ 35), and lymphoid malignancies in 23% (n ¼ 33), and other diagnoses in 25% (n ¼ 10). Forty-two patients (62%) received a NMA conditioning regimen. In 54 patients (80%) there was gender mismatch between the two units, and in 55 patients (81%) there was ABO incompatibility between the two units. The median follow-up time was 2 years (range 1.0-3.2 years).
Cord predominance, investigated descriptively by looking the median dose between the predominant and non-predominant units among the study population, was defined as X70% of chimerism by day þ 100 post transplantation by PCR of informative polymorphic variable number tandem repeat and more commonly, short tandem repeat regions in the recipient and donor as previously described. 7 Donor chimerism was determined in bone marrow at days 21, 100, 180, 360 and 720 after transplantation, with additional time points as needed. Engraftment studies showed that by day þ 100 and subsequent time points after transplantation, a median chimerism from the predominant unit 470% was observed in 97% and 94% of MA and NMA, respectively (P ¼ 0.35).
CXCR4 was highly expressed in 98% of the CD34 þ cells in UCB grafts, with no significant differences between the predominant and non-predominant units regarding MFI (Figures 1a-d) . It has been reported that UCB CD34 þ CXCR4 þ cell subset ranges from 8 to 80%. 2, 10 Discrepancies may, at least in part, be due to technical differences on UCB processing, staining and source. In our study, we only included clinically utilized UCB units obtained from six cord blood banks in contrast to Timeus et al. 10 and Ohno et al.
2 that used 'research' cord blood units. In part, cryopreservation may have been produced a slight decrease on CXCR4 expression levels as reported. 10 In our study, thawing and staining process were uniform for all units, and CXCR4 expression should not have been significantly influenced by this factors.
It has been shown that CXCR4 is involved in homing and engraftment. 11 In addition, priming of hematopoietic progenitors with reagents, such as complement fragment 3a 12 and prostaglandins, 13 leads to CXCR4 activation with increased migration towards a SDF1 gradient and improved engraftment. The proportion of CD34 þ CXCR4 þ cells in the predominant UCB unit was 1.7% (range 0.5-6.5%) vs 2.0% (0.6-5.2%) in the nonpredominant. The intensity of expression of CXCR4 on CD34 þ cells, as measured by MFI, was similar for the predominant (36.5; range 3.7-214) and non-predominant unit (44.1; range 3.7-219) (P ¼ 0.34). Thus, both the proportion of CD34 þ CXCR4 þ cells and the intensity of CXCR4 expression on CD34 þ cells were found to be similar between the predominant and non-predominant units (Table 1) . We also found no difference in the time to neutrophil recovery whether the CXCR4 expression on the predominant unit was above (18 days, range 6-40) or below (22 days; range 0-39) the median MFI (P ¼ 0.26).
Although homing of HSCs depends the CXCR4/SDF1 axis, the expression of CXCR4 in UCB CD34 þ cells was not associated with unit predominance (Figure 1e ). Subsequent to homing and engraftment, as shown by our group 7 and others, 8 the unit that will provide long-term lympho-hematopoietic recovery is largely determined by T-cell content and interactions between the T cells of the two donor UCB units. 5 Although CD34 þ viability has also been shown to predict predominance after dUCB transplantation, it is only predictive when one of the two units' viability is below 75% 6 and was not a factor in our study. In summary, our data shows that in dUCB transplantation CXCR4 expression is not a predictor of long-term predominant UCB unit. Although CXCR4 expression on UCB CD34 þ cells did not influence unit predominance in our study, it is possible that function/activation rather than expression alone may influence homing, engraftment and possibility of long-term predominance. Thus, as most CD34 þ cell express CXCR4, functional responsiveness to a SDF1 gradient in a transwell system may be a better parameter to be considered in future studies. An ongoing phase I/II study, based on pre-clinical data, 12, 13 is testing this hypothesis by priming one of two UCB units composing the graft with C3a and Prostaglandin E2.
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The authors declare no conflict of interest. Acute leukemia is the most common childhood cancer. In 30-40% of the patients, leukemia carries a high-risk cytogenetic aberration, responds slowly to therapy, or relapses. To be cured, these patients require treatment with allogeneic hematopoietic stem cell transplantation. Permanent ovarian failure is observed in 70-90% of young patients following hematopoietic stem cell transplantation. 1, 2 Rapid progress in the development of strategies to generate fertile gametes from cryopreserved ovarian tissue has opened possibilities to preserve fertility of these young girls and women. In adults, the cryopreservation of ovarian cortex before gonadotoxic chemotherapy and autotransplantation of thawed tissue back to the cured patient has been shown to re-establish the menstrual cycles and lead to the birth of healthy children. 3 Cryopreservation of ovarian tissue from young, sexually immature girls has been proposed similarly to allow long-term storage of large numbers of primordial follicles for fertility preservation. 4, 5 Although transplanted children and adolescents constitute the most important group of patients who would benefit from the novel ovarian autotransplantation techniques, concern has been expressed about the method possibly carrying a risk of leukemia relapse originating from residual leukemic cells in the ovarian tissue. 6, 7, 8 In order to evaluate whether the bone marrow-remission status influences the minimal residual leukemia (MRD) in ovarian samples, individual Ig/TCR (immunoglobulin/T-cell receptor) gene rearrangements and translocation-specific fusion gene products were analyzed by quantitative real-time PCR (qPCR). MRD was determined in six ovarian specimens collected at diagnosis of leukemia and in 10 collected at morphological remission induced by chemotherapy. Morphological bone marrow remission was defined as the restoration of normal hematopoiesis with a blast cell fraction of o5% by light microscopic examination. Bone marrow MRD status was analyzed by flow cytometry or qPCR and correlated with the simultaneously measured quantitative MRD in the ovarian tissue.
The study material consisted of nine consecutive ovarian samples from deceased childhood leukemia patients who had participated in a research project for fertility preservation at the Helsinki University Central Hospital during 1999-2012 and had a leukemia-specific marker that enabled qPCR analysis of MRD in the cryopreserved ovarian tissue. Ovarian samples from surviving girls (n ¼ 11) and those from the deceased girls with no leukemiaspecific marker (n ¼ 2) were excluded form the study. The patients underwent ovarian cryopreservation before hematopoietic stem cell transplantation at morphological bone marrow remission. Informed consent was obtained from the guardians and ageappropriate patients. The Research Ethics Committee of Helsinki University Hospital approved the study.
